
AMAG to sell MuGard in the US for Access Pharmaceuticals
Executive Summary
AMAG Pharmaceuticals Inc. (blood disorder therapy) has licensed exclusive US rights to the MuGard oral wound rinse in the US and its territories from Access Pharmaceuticals Inc. (supportive cancer care).
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com